6 Matching Annotations
  1. Sep 2026
  2. 54.241.53.176 54.241.53.176
    mct-25-1360-html.html
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    54.241.53.176/4d8acaa82df0b1249261f97f03c5b6ff417be932/mct-25-1360-html.html
  3. Jul 2026
  4. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov
    Capivasertib combines with trastuzumab deruxtecan to enhance anti-tumour activity in HER2-positive and HER2-low tumours
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    pmc.ncbi.nlm.nih.gov/articles/PMC13324342/
  5. Jan 2026
  6. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov
    Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    pmc.ncbi.nlm.nih.gov/articles/PMC12793832/
  7. Jul 2025
  8. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov
    M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    pmc.ncbi.nlm.nih.gov/articles/PMC12214875/
  9. Aug 2024
  10. www.ncbi.nlm.nih.gov www.ncbi.nlm.nih.gov
    Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    ncbi.nlm.nih.gov/pmc/articles/PMC11292196/
  11. Jan 2023
  12. www.ncbi.nlm.nih.gov www.ncbi.nlm.nih.gov
    AZD4625 is a Potent and Selective Inhibitor of KRASG12C
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    ncbi.nlm.nih.gov/pmc/articles/PMC9538594/